Date: 2014-10-21
Type of information: Licensing agreement
Compound: remede® System
Company: Sorin (Italy) Respicardia (USA - MN)
Therapeutic area: Cardiovascular diseases
Type agreement: licensing
Action mechanism: The remede® System is an implantable medical device that was designed for improved respiratory rhythm management. The remede® System delivers electrical pulses at night, during sleep, to restore a more normal breathing pattern and improve cardiovascular health in patients with Central Sleep Apnea. The remede® System consists of an implantable pulse generator, implantable leads, and an external system programmer.
Disease:
Details: * On October 21, 2014, Sorin Group, a global medical device company and a leader in the treatment of cardiovascular diseases, announced a $20 million minority investment in Respicardia, a developer of implantable therapies to improve Respiratory Rhythm Management™. Under the terms of the transaction, Sorin also acquired the exclusive right to distribute the remede® System for the next five years in selected countries in Europe and an exclusive option to acquire Respicardia in the future.
Financial terms:
Latest news:
